← Back to catalogue
ENQUIRE ABOUT THIS RESEARCH COMPOUND →
Performance & Recovery
CJC 1295 + DAC
10mg
CJC 1295 + DAC is a longer-acting GHRH analogue explored in research involving growth-hormone and IGF-1 signalling.
Research focusLonger-acting GHRH analogue research
PresentationLyophilised peptide · 10mg · 3 mL vial
Research overview
CJC-1295 is a synthetic GHRH analogue. The DAC modification was designed to extend systemic exposure through reversible albumin binding, allowing research into more sustained GH/IGF-1 pathway stimulation.
Evidence status
Limited human clinical research
Published human studies exist, but the evidence base is much smaller than for widely approved endocrine medicines. Broader performance or body-composition claims are not established by those studies.
Research use only. Not for human consumption. This page is educational and does not provide medical advice or dosing guidance.
Areas under investigation
- GHRH-receptor pharmacology
- Growth-hormone and IGF-1 signalling
- Extended-exposure peptide design
Explore the scientific literature
For primary-source reading, search the indexed biomedical literature and registered clinical studies. These links are provided as research gateways rather than endorsements of any particular finding.
PUBLISHED STUDY MAP
See a source-linked study design for CJC-1295 + DAC: population, route, timeframe and endpoint — without dosing recommendations.
OPEN STUDY MAP →